JP2017500017A - 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用 - Google Patents

生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用 Download PDF

Info

Publication number
JP2017500017A
JP2017500017A JP2016532136A JP2016532136A JP2017500017A JP 2017500017 A JP2017500017 A JP 2017500017A JP 2016532136 A JP2016532136 A JP 2016532136A JP 2016532136 A JP2016532136 A JP 2016532136A JP 2017500017 A JP2017500017 A JP 2017500017A
Authority
JP
Japan
Prior art keywords
culture
cells
cell
liters
cumulative amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016532136A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017500017A5 (https=
Inventor
ウィリアム シー． ヤン，
ウィリアム シー． ヤン，
ジウイー ル，
ジウイー ル，
ヤオ−ミン フアン，
ヤオ−ミン フアン，
ハン ユアン，
ハン ユアン，
ラシュミ クシルサガル，
ラシュミ クシルサガル，
トーマス リル，
トーマス リル，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of JP2017500017A publication Critical patent/JP2017500017A/ja
Publication of JP2017500017A5 publication Critical patent/JP2017500017A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/22—Zinc; Zn chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2016532136A 2013-12-20 2014-12-19 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用 Withdrawn JP2017500017A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361919629P 2013-12-20 2013-12-20
US61/919,629 2013-12-20
PCT/US2014/071701 WO2015095809A1 (en) 2013-12-20 2014-12-19 Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020000268A Division JP2020054388A (ja) 2013-12-20 2020-01-06 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用

Publications (2)

Publication Number Publication Date
JP2017500017A true JP2017500017A (ja) 2017-01-05
JP2017500017A5 JP2017500017A5 (https=) 2018-02-08

Family

ID=52347449

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016532136A Withdrawn JP2017500017A (ja) 2013-12-20 2014-12-19 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用
JP2020000268A Withdrawn JP2020054388A (ja) 2013-12-20 2020-01-06 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用
JP2022197095A Pending JP2023022317A (ja) 2013-12-20 2022-12-09 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020000268A Withdrawn JP2020054388A (ja) 2013-12-20 2020-01-06 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用
JP2022197095A Pending JP2023022317A (ja) 2013-12-20 2022-12-09 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用

Country Status (5)

Country Link
US (2) US20160289633A1 (https=)
EP (1) EP3083933B1 (https=)
JP (3) JP2017500017A (https=)
DK (1) DK3083933T3 (https=)
WO (1) WO2015095809A1 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017521057A (ja) * 2014-06-09 2017-08-03 ジェンザイム・コーポレーション シードトレイン法およびその使用
JP2020533983A (ja) * 2017-09-15 2020-11-26 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 目的のポリペプチドのラージスケールの製造間のオンラインバイオマス静電容量モニタリング
JP2021516971A (ja) * 2018-03-09 2021-07-15 嘉和生物▲薬▼▲業▼有限公司 上流生産プロセスでの段階的な分画による生体高分子の生産方法、生産モジュール、および生産における使用
JP2022527582A (ja) * 2019-04-11 2022-06-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ケト酸を含む細胞培養培地
JP2022540920A (ja) * 2019-07-16 2022-09-20 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 高密度連続接種の細胞培養方法及びその応用
JP2023553117A (ja) * 2020-12-08 2023-12-20 パートナー セラピューティクス インコーポレイテッド 顆粒球マクロファージコロニー刺激因子の製造
US12378517B2 (en) 2014-06-06 2025-08-05 Genzyme Corporation Perfusion culturing methods and uses thereof

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3083933T3 (da) 2013-12-20 2026-03-16 Biogen Ma Inc Anvendelse af perfusionssåningskulturer til forbedring af biofarmaceutisk fed-batch-produktionskapacitet og -produktkvalitet
US20180312802A1 (en) * 2015-11-02 2018-11-01 Ares Trading S.A. Methods for modulating production profiles of recombinant proteins in perfusion mode
CN116083344A (zh) 2016-01-26 2023-05-09 勃林格殷格翰国际公司 对连续流动搅拌釜反应器细胞培养系统的连接灌注
WO2018044699A1 (en) 2016-08-27 2018-03-08 3D Biotek, Llc Bioreactor
WO2019071076A1 (en) 2017-10-06 2019-04-11 Lonza Ltd. AUTOMATED CONTROL OF CELL CULTURE BY SPECTROSCOPY RAMAN
IL315801A (en) 2017-10-16 2024-11-01 Regeneron Pharma Perfusion bioreactor and methods of using it
KR20200083564A (ko) * 2017-11-13 2020-07-08 암젠 인크 단백질 산물을 제조하는 방법
KR20250111232A (ko) * 2017-12-11 2025-07-22 암젠 인크 이중특이적 항체 생성물의 연속 제조 공정
WO2019212921A1 (en) * 2018-04-29 2019-11-07 Regenxbio Inc. Scalable clarification process for recombinant aav production
US12071607B2 (en) * 2018-06-01 2024-08-27 Lonza Ltd. Midscale model for organic growth and phasing
EP3818078B1 (en) * 2018-07-03 2024-02-28 Bristol-Myers Squibb Company Methods of producing recombinant proteins
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
EP3875595A4 (en) * 2018-11-02 2022-07-13 Kyowa Kirin Co., Ltd. Liquid medium preparation method
US20220098556A1 (en) * 2019-01-25 2022-03-31 Biogen Ma Inc. Seed culture process for aav production
JP2022543781A (ja) * 2019-08-01 2022-10-14 ブリストル－マイヤーズ スクイブ カンパニー フェッドバッチ細胞培養におけるタンパク質産生性の改良方法
US12529024B2 (en) 2019-11-15 2026-01-20 Lonza Ltd Process and system for producing an inoculum
BR112023017717A2 (pt) 2021-05-03 2024-01-09 Boehringer Ingelheim Int Método para produção de espesolimabe
WO2023114901A2 (en) 2021-12-15 2023-06-22 Oxford Biomedica Solutions Llc Methods and compositions for the production of adeno-associated virus
CN119137263A (zh) * 2022-03-07 2024-12-13 奥特吉尼克斯制药公司 改进的分批aav产生系统和方法
CN120153061A (zh) * 2022-09-06 2025-06-13 美国安进公司 精简灌注细胞培养方法
WO2026033566A2 (en) 2024-08-09 2026-02-12 Omnibrx Biotechnologies Private Limited A multistage bioreactor system and method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008511329A (ja) * 2004-08-27 2008-04-17 ワイス・リサーチ・アイルランド・リミテッド ポリペプチドの製造

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
AU2002226028A1 (en) 2000-11-14 2002-05-27 Board Of Regents, Unversity Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
CA2431230C (en) 2000-12-20 2011-02-22 Bayer Pharmaceuticals Corporation A device and method for seed-train expansion of mammalian cells
KR20040039328A (ko) 2001-09-04 2004-05-10 메르크 파텐트 게엠베하 변형된 펙터 ⅸ
WO2003071271A1 (en) 2002-02-21 2003-08-28 Tokyo Gas Company Limited Test agents for evaluating pharmacological effect of drug, and method and reagents for screening drug having excellent administration effect and/or little side effect from among drugs comprising enzymes, enzyme inhibitors or receptor ligands and/or produrgs thereof
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
CA2510003A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
CA2557046A1 (en) * 2004-03-05 2005-10-13 John Crowley Process for cell culturing by continuous perfusion and alternating tangential flow
EP2423305A1 (en) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
TWI456062B (zh) * 2006-09-13 2014-10-11 Abbvie Inc 細胞培養改良
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
AU2008311973B2 (en) 2007-10-15 2013-10-03 Cangene Corporation Human Factor IX variants with an extended half life
JP2011517950A (ja) 2008-04-16 2011-06-23 バイエル・ヘルスケア・エルエルシー 第ｉｘ因子の部位特異的修飾
CA2721683A1 (en) 2008-04-16 2009-11-12 Bayer Healthcare Llc Modified factor ix polypeptides and uses thereof
CN102105582A (zh) 2008-04-21 2011-06-22 诺沃-诺迪斯克有限公司 高糖基化人凝血因子ix
RU2010147652A (ru) * 2008-04-23 2012-05-27 Симфоген А/С (Dk) Способы производства поликлонального белка
UA106047C2 (uk) * 2008-06-13 2014-07-25 Сентокор Орто Байотек Інк. Спосіб отримання високої щільності життєздатних клітин в культурі клітин ссавців
PL3326643T3 (pl) 2009-12-06 2021-10-25 Bioverativ Therapeutics Inc. Chimeryczne i hybrydowe polipeptydy czynnika VIII-FC oraz sposoby ich zastosowania
JP2013517776A (ja) * 2010-01-25 2013-05-20 ベントリア・バイオサイエンス タンパク質の生成を改善するための方法および組成物
SG10201505217WA (en) 2010-07-09 2015-08-28 Biogen Hemophilia Inc Chimeric clotting factors
UA126265C2 (uk) 2010-07-09 2022-09-14 Байовератів Терапьютікс Інк. Поліпептид фактора іх і спосіб його застосування
EP2591101B1 (en) 2010-07-09 2018-11-07 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
CN103415610B (zh) 2011-03-18 2016-10-19 通用电气健康护理生物科学股份公司 用于培养细胞的弹性袋
DK2726600T3 (en) * 2011-07-01 2017-05-15 Amgen Inc Mammalian Cell Culture
DK3083933T3 (da) 2013-12-20 2026-03-16 Biogen Ma Inc Anvendelse af perfusionssåningskulturer til forbedring af biofarmaceutisk fed-batch-produktionskapacitet og -produktkvalitet

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008511329A (ja) * 2004-08-27 2008-04-17 ワイス・リサーチ・アイルランド・リミテッド ポリペプチドの製造

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PADAWER ISHAI ET AL.: "Case Study: An accelerated 8-day monoclonal antibody production process based on high seeding densit", BIOTECHNOLOGY PROGRESS, vol. 29, no. 3, JPN6018041861, 18 April 2013 (2013-04-18), pages 829 - 832, ISSN: 0004230568 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12378517B2 (en) 2014-06-06 2025-08-05 Genzyme Corporation Perfusion culturing methods and uses thereof
JP2017521057A (ja) * 2014-06-09 2017-08-03 ジェンザイム・コーポレーション シードトレイン法およびその使用
JP2020533983A (ja) * 2017-09-15 2020-11-26 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 目的のポリペプチドのラージスケールの製造間のオンラインバイオマス静電容量モニタリング
JP2021516971A (ja) * 2018-03-09 2021-07-15 嘉和生物▲薬▼▲業▼有限公司 上流生産プロセスでの段階的な分画による生体高分子の生産方法、生産モジュール、および生産における使用
JP2022527582A (ja) * 2019-04-11 2022-06-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ケト酸を含む細胞培養培地
JP7684224B2 (ja) 2019-04-11 2025-05-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ケト酸を含む細胞培養培地
JP2022540920A (ja) * 2019-07-16 2022-09-20 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 高密度連続接種の細胞培養方法及びその応用
JP7680418B2 (ja) 2019-07-16 2025-05-20 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 高密度連続接種の細胞培養方法及びその応用
JP2023553117A (ja) * 2020-12-08 2023-12-20 パートナー セラピューティクス インコーポレイテッド 顆粒球マクロファージコロニー刺激因子の製造

Also Published As

Publication number Publication date
JP2020054388A (ja) 2020-04-09
DK3083933T3 (da) 2026-03-16
US20250382568A1 (en) 2025-12-18
EP3083933B1 (en) 2026-01-21
WO2015095809A1 (en) 2015-06-25
EP3083933A1 (en) 2016-10-26
JP2023022317A (ja) 2023-02-14
US20160289633A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
US20250382568A1 (en) Use of perfusion seed cultures to improve biopharmaceutical fedbatch production capacity and product quality
KR101540124B1 (ko) 항노화 화합물을 사용하는 단백질의 생산 방법
KR102604988B1 (ko) 관류 배지
KR102604992B1 (ko) 관류 배지
US10676772B2 (en) Control of protein glycosylation by culture medium supplementation and cell culture process parameters
JP7495483B2 (ja) 濃縮灌流培地
JP2024050574A (ja) 哺乳動物細胞培養物によって生産されるニューブラスチン抗体
US20150353883A1 (en) Medium Supplements for Improved Process Performance
US12441980B2 (en) Methods for overcoming glutamine deprivation during mammalian cell culture
US10717965B2 (en) Mammalian cell culture-produced neublastin antibodies
JP2021503916A (ja) 哺乳動物細胞の培養方法
US20170029859A1 (en) Medium supplements for improved process performance
US20170327786A1 (en) Hypotaurine, GABA, Beta-Alanine, and Choline for Control of Waste Byproduct Accumulation in Mammalian Cell Culture Process
HK1142095B (en) Methods of protein production using anti-senescence compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171219

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181025

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190322

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200106

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200114

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20200313

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20200319